The first FDA-approved anti-VEGF for diabetic retinopathy (DR) with or without DME 1

Choose LUCENTIS to treat diabetic retinopathy

LUCENTIS demonstrates significant regression in retinopathy across DR subtypes and is indicated to treat DR with or without DME. 1


Moderately Severe/Severe NPDR

Severe NPDR

Mild PDR

Moderate PDR

High-Risk PDR

ETDRS, Early Treatment Diabetic Retinopathy Scale; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; VEGF, vascular endothelial growth factor.

Resources for your patients.
LUCENTIS Co-pay Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.